Radical food: Nation of Islam and Latter-day Saint culinary ideals (1930-1980)

This dissertation addresses how from 1930 to 1980 two minority religious groups, the Nation of Islam and the Church of Jesus Christ of Latter-day Saints (Mormons), used food to express their separate and superior status as God's chosen people while at the same time engaging the values of broader American culture. Outsiders in American religion are, in many ways, consummate insiders seeking to craft an ideal society. Historian R. Laurence Moore has argued that, by inventing themselves through a sense of opposition, religious outsiders contributed substantially to what we think of as American culture. This study of Mormons and Nation Muslims focuses more on the way values from American culture also shaped belief and behavior in two outsider groups. I build on Moore's insight to conclude that, at the same time outsider groups rebelled against what they defined as white Protestants' transgressions or faults, they negotiated their own worth in relation to white Protestant values that they had quite thoroughly internalized. The processes of cultural assimilation and separation for these outsider religious groups happened simultaneously. As each group worked out what its separateness and superiority meant in everyday patterns of eating, each developed a cuisine that represented its deeply held religious and cultural priorities. In Mormonism, the greatest value was self-sufficiency, while for the Nation it was health; both groups also used foodways to stress refinement and a sense of chosenness. This study analyzes food habits in their entirety, discussing not only prohibitions, as other scholars do, but also recipes, fasting, food production, and table manners. Major sources include magazine and newspaper articles, speech transcripts, oral history interviews, devotional literature, and cookbooks. Food habits tell how Nation Muslims and Mormons invoked traditional American values but applied those values in their own way in order to be "in but not of" the world.2019-05-31T00:00:00

The Stroke Outcomes Study 2 (SOS2): a prospective, analytic cohort study of depressive symptoms after stroke

<p>Abstract</p> <p>Background</p> <p>Mood disorder is recognised as an important and common problem after stroke but little is known about the longer term effects of mood on functional outcomes. This protocol paper describes the Stroke Outcomes Study 2 (SOS2), a research study conducted in two large acute NHS Trusts in the North of England, which was designed to investigate the impact of early depressive symptoms on outcomes after an acute stroke.</p> <p>Methods and design</p> <p>SOS2 was a prospective cohort study that aimed to recruit patients in the first few weeks after a stroke, and to follow them up at regular intervals for one year thereafter in order to describe the trajectory of psychological symptoms and study their impact on physical functional recovery. Measures of mood and function were completed at baseline (approximately 3 weeks) and at four follow-up time-points: approximately 9, 13, 26 and 52 weeks after the index stroke.</p> <p>Discussion</p> <p>Recruiting patients to research studies soon after an acute stroke is difficult. Mortality following stroke is approximately 30% and in the region of half the patients that survive the initial event are significantly disabled. Together these factors reduced the number of patients available to participate in SOS2 but once recruited to the study the drop-out rate was relatively low. During the recruitment period over 6000 admissions for stroke or query stroke were screened for eligibility. A cohort of 592 study participants was finally achieved.</p

International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways.

Primary biliary cirrhosis (PBC) is a classical autoimmune liver disease for which effective immunomodulatory therapy is lacking. Here we perform meta-analyses of discovery data sets from genome-wide association studies of European subjects (n=2,764 cases and 10,475 controls) followed by validation genotyping in an independent cohort (n=3,716 cases and 4,261 controls). We discover and validate six previously unknown risk loci for PBC (Pcombined<5 × 10(-8)) and used pathway analysis to identify JAK-STAT/IL12/IL27 signalling and cytokine-cytokine pathways, for which relevant therapies exist

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

Background: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on postoperative recovery needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. This study reports 30-day mortality and pulmonary complication rates in patients with perioperative SARS-CoV-2 infection. Methods: This international, multicentre, cohort study at 235 hospitals in 24 countries included all patients undergoing surgery who had SARS-CoV-2 infection confirmed within 7 days before or 30 days after surgery. The primary outcome measure was 30-day postoperative mortality and was assessed in all enrolled patients. The main secondary outcome measure was pulmonary complications, defined as pneumonia, acute respiratory distress syndrome, or unexpected postoperative ventilation. Findings: This analysis includes 1128 patients who had surgery between Jan 1 and March 31, 2020, of whom 835 (74·0%) had emergency surgery and 280 (24·8%) had elective surgery. SARS-CoV-2 infection was confirmed preoperatively in 294 (26·1%) patients. 30-day mortality was 23·8% (268 of 1128). Pulmonary complications occurred in 577 (51·2%) of 1128 patients; 30-day mortality in these patients was 38·0% (219 of 577), accounting for 81·7% (219 of 268) of all deaths. In adjusted analyses, 30-day mortality was associated with male sex (odds ratio 1·75 [95% CI 1·28–2·40], p\textless0·0001), age 70 years or older versus younger than 70 years (2·30 [1·65–3·22], p\textless0·0001), American Society of Anesthesiologists grades 3–5 versus grades 1–2 (2·35 [1·57–3·53], p\textless0·0001), malignant versus benign or obstetric diagnosis (1·55 [1·01–2·39], p=0·046), emergency versus elective surgery (1·67 [1·06–2·63], p=0·026), and major versus minor surgery (1·52 [1·01–2·31], p=0·047). Interpretation: Postoperative pulmonary complications occur in half of patients with perioperative SARS-CoV-2 infection and are associated with high mortality. Thresholds for surgery during the COVID-19 pandemic should be higher than during normal practice, particularly in men aged 70 years and older. Consideration should be given for postponing non-urgent procedures and promoting non-operative treatment to delay or avoid the need for surgery. Funding: National Institute for Health Research (NIHR), Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, NIHR Academy, Sarcoma UK, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Characterization of a stratigraphically constrained gas hydrate system along the western continental margin of Svalbard from ocean bottom seismometer data

The ongoing warming of bottom water in the Arctic region is anticipated to destabilize some of the gas hydrate present in shallow seafloor sediment, potentially causing the release of methane from dissociating hydrate into the ocean and the atmosphere. Ocean-bottom seismometer (OBS) experiments were conducted along the continental margin of western Svalbard to quantify the amount of methane present as hydrate or gas beneath the seabed. P- and S-wave velocities were modeled for five sites along the continental margin, using ray-trace forward modeling. Two southern sites were located in the vicinity of a 30 km long zone where methane gas bubbles escaping from the seafloor were observed during the cruise. The three remaining sites were located along an E-W orientated line in the north of the margin. At the deepest northern site, Vp anomalies indicate the presence of hydrate in the sediment immediately overlying a zone containing free gas up to 100-m thick. The acoustic impedance contrast between the two zones forms a bottom-simulating reflector (BSR) at approximately 195 m below the seabed. The two other sites within the gas hydrate stability zone (GHSZ) do not show the clear presence of a BSR or of gas hydrate. However, anomalously low Vp, indicating the presence of free gas, was modeled for both sites. The hydrate content was estimated from Vp and Vs, using effective-medium theory. At the deepest northern site, modeling suggests a pore-space hydrate concentration of 7–12%, if hydrate forms as part of a connected framework, and about 22% if it is pore-filling. At the two other northern sites, located between the deepest site and the landward limit of the GHSZ, we suggest that hydrate is present in the sediment as inclusions. Hydrate may be present in small quantities at these two sites (4–5%) of the pore space. The variation in lithology for the three sites indicated by high-resolution seismic profiles may control the distribution, concentration and formation of hydrate and free gas